A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients

Next Previous
Trial Profile

A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 26 May 2016

At a glance

  • Drugs Glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms GEM-1
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 26 May 2016 According to Vectura media release, Seebri™ Neohaler was approved by the FDA in October 2015.
    • 20 May 2015 Results were presented at the American Thoracic Society International Conference, according to a Novartis media release.
    • 20 May 2015 Results published in a Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top